Structure Therapeutics Inc. (GPCR)
| Market Cap | 3.38B +208.7% |
| Revenue (ttm) | n/a |
| Net Income | -214.84M |
| EPS | -3.22 |
| Shares Out | 71.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 601,744 |
| Open | 48.93 |
| Previous Close | 49.22 |
| Day's Range | 46.96 - 49.20 |
| 52-Week Range | 18.26 - 94.90 |
| Beta | -1.51 |
| Analysts | Strong Buy |
| Price Target | 104.77 (+121.17%) |
| Earnings Date | Aug 6, 2026 |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for GPCR stock is "Strong Buy." The 12-month stock price target is $104.77, which is an increase of 121.17% from the latest price.
News
Structure Therapeutics price target raised to $111 from $101 at Canaccord
Canaccord raised the firm’s price target on Structure Therapeutics (GPCR) to $111 from $101 and keeps a Buy rating on the shares. The firm said Structure reported financial results and…
Structure Therapeutics price target lowered to $97 from $100 at Citi
Citi lowered the firm’s price target on Structure Therapeutics (GPCR) to $97 from $100 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
Structure Therapeutics price target lowered to $110 from $113 at Citizens
Citizens lowered the firm’s price target on Structure Therapeutics (GPCR) to $110 from $113 and keeps an Outperform rating on the shares. Structure Therapeutics continues to advance a differentiated o...
Structure Therapeutics Earnings release: Q2 2026
Structure Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Structure Therapeutics Quarterly report: Q2 2026
Structure Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Structure Therapeutics Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and executive compensation, with all proposals passing. Strategic updates highlighted clinical progress in chronic weight management and a strong capital position to support ongoing trials.
The Next Phase Of The Obesity Drug Race
Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others like Structure Therapeutics and Zealand Phar...
Structure Therapeutics price target lowered to $70 from $100 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Structure Therapeutics (GPCR) to $70 from $100 and keeps a Buy rating on the shares. The firm says retatrutide’s “clean” low-dose profile…
Structure Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Recent ADA data confirmed best-in-class efficacy for oral obesity therapy, with up to 16% weight loss and rapid market adoption. Phase III will start in Q3, focusing on patient-friendly titration and long-term maintenance, while amylin and combination programs advance with robust funding.
Structure's experimental obesity pill shows no signs of liver injury
Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of drug-induced liver injury, and patients continued to lose weight even on the lower doses of the dru...
Structure Therapeutics announces ACCESS trial data published in Nature Medicine
Structure Therapeutics (GPCR) announced a publication in Nature Medicine detailing results from the Phase 2b ACCESS clinical trial of aleniglipron for the treatment of people living with obesity and/o...
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
Publication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecul...
Structure Therapeutics Slides: Corporate presentation
Structure Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
Structure Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Oral GLP-1 therapies are rapidly expanding the obesity market, with strong demand and high efficacy demonstrated by aleniglipron. The company is advancing both GLP-1 and Amylin programs, supported by a robust IP portfolio and $1.5B in cash, with key data and phase III trials upcoming.
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for meta...
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially com...
Structure Therapeutics Earnings release: Q1 2026
Structure Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Structure Therapeutics Quarterly report: Q1 2026
Structure Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me...
Canaccord starts Structure Therapeutics on oral weight loss pipeline
Canaccord initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $101 price target The stock in premarket trading is up 3% to $46.90. The firm says Structure is…
Structure Therapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $101 price target
Structure Therapeutics Proxy statement: Proxy filing
Structure Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Structure Therapeutics appoints Matthew Lang as COO
Structure Therapeutics (GPCR) announced the appointment of Matthew Lang as COO and general counsel. Lang most recently served as chief legal officer and secretary at Metsera.
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me...
Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Structure Therapeutics (GPCR) to $100 from $114 and keeps a Buy rating on the shares. While the company reported “breakthrough” 44-week data…